NCT01868464View on ClinicalTrials.gov

Challenge Model for Assessment of Human TB Immunity

PHASE1CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

May 28, 2014

Primary Completion Date

December 18, 2017

Study Completion Date

December 18, 2017

Conditions
Tuberculosis
Interventions
BIOLOGICAL

BCG TICE strain

All doses: Tice Bacillus Calmette-Guerin (BCG) will be administered as a single 0.1 ml ID injection over the deltoid muscle of the preferred arm. Groups 1 - 4 will receive one dose of Tice BCG intradermally at 2x10\^6 cfu, 4x10\^6 cfu, 8x10\^6 cfu and 16x10\^6 cfu, respectively.

Trial Locations (2)

30030-1705

Emory Vaccine Center - The Hope Clinic, Decatur

63104-1015

Saint Louis University - Center for Vaccine Development, St Louis

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01868464 - Challenge Model for Assessment of Human TB Immunity | Biotech Hunter | Biotech Hunter